Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)

Blood Cancer Journal, Published online: 15 November 2022; doi:10.1038/s41408-022-00748-9Following treatment with DNMTI therapy, patients with MDS have differences in survival according to the quality of their treatment response. In this analysis, patients who achieve CRh had similar OS compared to those meeting standard “CR” criteria, which was better than the survival of those with other treatment responses (p 

Source: Blood Cancer Journal - November 15, 2022 Category: Hematology Authors: Andrew M. Brunner Alexander Gavralidis Najla Al Ali Anthony Hunter Rami Komrokji Amer Zeidan David A. Sallman Source Type: research